Opiant Pharmaceuticals to Report Fourth Quarter 2021 Financial Results and Host Conference Call and Webcast on March 15, 2022
Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) will report its fourth quarter 2021 financial results and pipeline updates on March 15, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) will report its fourth quarter 2021 financial results and pipeline updates on March 15, 2022, after market close. The management team will host a conference call at 4:30 p.m. ET that same day, which can be accessed via phone or live webcast. Opiant is known for developing NARCAN® Nasal Spray and is focused on creating new medications for addiction and overdose treatment.
Positive
- Opiant is developing a strong portfolio of medicines for addiction and overdose.
- The upcoming conference call may provide insights into financial performance and pipeline advancements.
Negative
- None.
Details
News Market Reaction – OPNT
The recorded move for OPNT in the trading session of this news was -2.79%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SANTA MONICA, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report fourth quarter 2021 financial results and pipeline updates on Tuesday, March 15, 2022, after U.S. financial markets close.
The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Tuesday, March 15, 2022. To access the call, please dial 1-877-407-0792 in the U.S., or 1-201-689-8263, outside the U.S. and provide the conference ID number: 13726931. To access the live webcast, please visit https://themediaframe.com/mediaframe/webcast.html?webcastid=FPHqejQp. Following the live webcast, an archived version of the call will be available on the website.
| Tuesday March 15 @ 4:30 pm ET | |
| Domestic: | 1-877-407-0792 |
| International: | 1-201-689-8263 |
| Conference ID: | 13726931 |
| Webcast: | https://themediaframe.com/mediaframe/webcast.html?webcastid=FPHqejQp |
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit: www.opiant.com and follow Opiant on Twitter (@Opiant_Pharma).
For Media and Investor Inquiries:
Ben Atkins, Opiant
(310) 598-5410
batkins@opiant.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.